Progestogens in prostatic cancer.
A series of 20 patients with a histological diagnosis of prostatic cancer were treated with high doses of MAP (6alpha-methyl-17alpha-hydroxyprogesterone acetate). No response was noted in 9 patients with prostatic cancer in relapse. Objective and/or subjective response was noted in 6 of 11 patients who were untreated at the time of diagnosis.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D004305:Dose-Response Relationship, Drug; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D006065:Gonadotropins, Pituitary; D013739:Testosterone; D000135:Acid Phosphatase; D008525:Medroxyprogesterone